We are live on ! Find out more
AEGR

Aegerion Pharmaceuticals
AEGR

Delisted

AEGR was delisted on the 29th of November, 2016.

Back to rankings

131 hedge funds and large institutions have $1.24B invested in Aegerion Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 50 increasing their positions, 29 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

72% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 29

13% more capital invested

Capital invested by funds: $1.09B → $1.24B (+$144M)

2% more funds holding

Funds holding: 129 → 131 (+2)

6% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 32

39% less call options, than puts

Call options by funds: $32M | Put options by funds: $52.3M

Holders
131
Holders Change
+2
Holders Change %
+1.55%
% of All Funds
3.8%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.12%
New
34
Increased
50
Reduced
29
Closed
32
Calls
$32M
Puts
$52.3M
Net Calls
-$20.2M
Net Calls Change
-$26.2M

Top Buyers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
+$65.9M
2
Bank of America
Bank of America
North Carolina
+$18.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.6M
4
HM
HealthCor Management
New York
+$14.4M
5
Morgan Stanley
Morgan Stanley
New York
+$13.8M

Top Sellers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$38M
2
BBA
Baker Bros. Advisors
New York
-$13.3M
3
TCM
Tamarack Capital Management
California
-$11.7M
4
PHS
PFM Health Sciences
California
-$10.8M
5
FAM
Fred Alger Management
New York
-$6.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Credit Suisse
Switzerland
$9.17M +$371K +11,948 +5%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$9.12M +$5.1M +164,317 +151%
Prudential Financial
28
Prudential Financial
New Jersey
$8.56M +$6.29M +202,604 +377%
MFP
29
Michael F. Price
$8.01M – – –
Bank of Montreal
30
Bank of Montreal
Ontario, Canada
$7.16M -$2.57M -82,826 -28%
Millennium Management
31
Millennium Management
New York
$6.63M -$3.54M -114,134 -36%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$5.87M +$325K +10,463 +6%
Norges Bank
33
Norges Bank
Norway
$5.47M +$4.94M +159,137 +3,315%
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$5.44M +$172K +5,539 +4%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$5.19M +$309K +9,958 +7%
CCM
36
Cadian Capital Management
New York
$5.01M +$4.66M +150,000 New
CCA
37
Catalyst Capital Advisors
New York
$4.42M +$1.43M +46,000 +53%
EAM
38
EverPoint Asset Management
Connecticut
$4.01M +$2.64M +85,000 +243%
TI
39
Turner Investments
Pennsylvania
$3.94M -$23K -740 -0.6%
TCIM
40
TIAA CREF Investment Management
New York
$3.89M -$74K -2,385 -2%
BA
41
BlackRock Advisors
Delaware
$3.73M +$1.6M +51,528 +85%
DAM
42
Deltec Asset Management
New York
$3.65M +$96.2K +3,100 +3%
Group One Trading
43
Group One Trading
Illinois
$3.4M -$283K -9,123 -8%
GC
44
Guggenheim Capital
Illinois
$3.05M +$66.5K +2,144 +2%
Renaissance Technologies
45
Renaissance Technologies
New York
$2.97M +$388K +12,500 +16%
T. Rowe Price Associates
46
T. Rowe Price Associates
Maryland
$2.91M +$99.3K +3,200 +4%
RHJA
47
Rice Hall James & Associates
California
$2.89M +$917K +29,557 +52%
BIM
48
BlackRock Investment Management
Delaware
$2.71M +$18.8K +607 +0.8%
TAM
49
Tealwood Asset Management
Minnesota
$2.66M +$1.95M +62,675 +366%
MAA
50
Managed Account Advisors
New Jersey
$2.57M -$1.13M -36,373 -32%
1
2
3 4 5

AEGR Hedge Fund Activity: Q3 2014 in Review

131 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q3 2014, worth a combined $1.24B — up 13% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new AEGR positions and 32 closed out — a net gain of 2 holders — while 50 added to existing stakes and 29 trimmed.

The largest buyer was Scopia Capital Management, adding an estimated $65.9M. The largest seller was Lord, Abbett & Co, cutting an estimated $38M.

  • 131 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q3 2014, up from 129 in Q2 2014.
  • Funds reported $1.24B of Aegerion Pharmaceuticals stock for Q3 2014, up 13% quarter-over-quarter.
  • 34 funds opened new Aegerion Pharmaceuticals positions in Q3 2014 and 32 closed out, a net change of +2 holders.
  • The largest Aegerion Pharmaceuticals buyer in Q3 2014 was Scopia Capital Management, an estimated $65.9M added.
  • The largest Aegerion Pharmaceuticals seller in Q3 2014 was Lord, Abbett & Co, an estimated $38M sold.

Based on aggregated 13F filings for Q3 2014.